NASDAQ:APTO Aptose Biosciences (APTO) Stock Price, News & Analysis $0.40 -0.01 (-2.47%) (As of 09/18/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Aptose Biosciences alerts: Email Address About Aptose Biosciences Stock (NASDAQ:APTO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aptose Biosciences alerts:Sign Up Key Stats Today's Range$0.39▼$0.4150-Day Range$0.35▼$0.7352-Week Range$0.33▼$3.45Volume169,162 shsAverage Volume243,396 shsMarket Capitalization$7.16 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company OverviewAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More… The #1 Crypto for AI (Ad)We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. Aptose Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 39th PercentileAptose Biosciences scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAptose Biosciences has received no research coverage in the past 90 days.Read more about Aptose Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aptose Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.88% of the float of Aptose Biosciences has been sold short.Short Interest Ratio / Days to CoverAptose Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptose Biosciences has recently increased by 167.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.88% of the float of Aptose Biosciences has been sold short.Short Interest Ratio / Days to CoverAptose Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptose Biosciences has recently increased by 167.21%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.22 News SentimentAptose Biosciences has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aptose Biosciences this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for APTO on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows8 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Aptose Biosciences is held by insiders.Percentage Held by InstitutionsOnly 26.62% of the stock of Aptose Biosciences is held by institutions.Read more about Aptose Biosciences' insider trading history. Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address APTO Stock News HeadlinesAptose Biosciences Inc (LTI.BE)September 12, 2024 | sg.finance.yahoo.comAptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.comSeptember 11, 2024 | americanbankingnews.comKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…September 18, 2024 | Paradigm Press (Ad)Aptose Announces Results from Special Meeting of ShareholdersSeptember 5, 2024 | globenewswire.comWall Street Set to Open Shortened Week Lower Tuesday as Investors Await Manufacturing DataSeptember 4, 2024 | msn.comAptose Biosciences secures funds for AML treatment developmentSeptember 3, 2024 | finance.yahoo.comAptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop TuspetinibAugust 30, 2024 | globenewswire.comAptose Biosciences Inc: Analyst Forecasts and Stock AnalysisAugust 30, 2024 | theglobeandmail.comSee More Headlines APTO Stock Analysis - Frequently Asked Questions How have APTO shares performed this year? Aptose Biosciences' stock was trading at $2.54 at the beginning of the year. Since then, APTO shares have decreased by 84.4% and is now trading at $0.3955. View the best growth stocks for 2024 here. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) announced its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.15. When did Aptose Biosciences' stock split? Shares of Aptose Biosciences reverse split on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Aptose Biosciences' major shareholders? Aptose Biosciences' top institutional investors include Armistice Capital LLC (9.46%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include William G Rice, Bernd R Seizinger, Denis R Burger, Erich Platzer and Rafael Bejar. View institutional ownership trends. How do I buy shares of Aptose Biosciences? Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings8/08/2024Today9/18/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:APTO CUSIPN/A CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$18.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,184.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-5,683.22% Return on Assets-279.77% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.19) per share Price / Book-2.07Miscellaneous Outstanding Shares18,109,000Free Float17,276,000Market Cap$7.13 million OptionableNo Data Beta1.25 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:APTO) was last updated on 9/18/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.